Inflammatory breast cancers in Tunisia and France show similar immunophenotypes

Breast

Volumn 16, Issue 4, 2007, Pages 352-358

  Charafe Jauffret, Emmanuelle ^a,b   Mrad, Karima ^c   Intidhar LABIDI, Sana ^c   Ben Hamida, Azza ^c   Ben Romdhane, Khaled ^c   Ben Abdallah, Mansour ^c   Ginestier, Christophe ^a   Esterni, Benjamin ^a   Birnbaum, Daniel ^a   Ben Ayed, Farhat ^c   Xerri, Luc ^a   Viens, Patrice ^a   Mezlini, Amel ^c   Jacquemier, Jocelyne ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

Immunohistochemistry; Inflammatory breast cancer; Tissue microarrays; Tunisia

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MUCIN 1; TAMOXIFEN; UVOMORULIN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CONTROLLED STUDY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; FRANCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFLAMMATION; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUNISIA;

EID: 34547446732     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.01.002     Document Type: Article

References (20)

1. Le M.G., Arriagada R., et al. Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer 6 5 (2005) 439-445
2. Mourali N., Levine P.H., et al. Rapidly progressing breast cancer (poussee evolutive) in Tunisia: studies on delayed hypersensitivity. Int J Cancer 22 1 (1978) 1-3
3. Ben Ahmed S., Aloulou S., et al. Breast cancer prognosis in Tunisian women: analysis of a hospital series of 729 patients. Sante Publique 14 3 (2002) 231-241
4. Levine P.H., Pogo B.G., et al. Increasing evidence for a human breast carcinoma virus with geographic differences. Cancer 101 4 (2004) 721-726
5. Maalej M., Frikha H., Ben Salem S., et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer 86 3 (1999) 302-306
6. Charafe-Jauffret E., Tarpin C., Bardou V.J., et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202 3 (2004) 265-273
7. Sloane J.P., Amendoeira I., Apostolikas N., et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 434 1 (1999) 3-10
8. Ginestier C., Charafe-Jauffret E., Penault-Llorca F., et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 202 3 (2004) 286-298
9. Amparo R.S., Angel C.D., Ana L.H., et al. Inflammatory breast carcinoma: pathological or clinical entity?. Breast Cancer Res Treat 64 3 (2000) 269-273
10. Colpaert CG, Vermeulen PB, Dirix LY, Van Marck EA. Commentary re: N. J. McCarthy et al., microvessel density, expression of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res. 8: 3857-3862, 2002. Clin Cancer Res 2003;9(10, Part 1):3815-6.
11. Gupta A., Deshpande C.G., and Badve S. Role of E-cadherins in development of lymphatic tumor emboli. Cancer 97 9 (2003) 2341-2347
12. Kleer C.G., van Golen K.L., Braun T., and Merajver S.D. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 14 5 (2001) 458-464
13. Lerebours F., Bieche I., and Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 7 2 (2005) 52-58
14. McCarthy N.J., Yang X., Linnoila I.R., et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8 12 (2002) 3857-3862
15. Van den Eynden G.G., Van da I., Van Laere S., et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 85 1 (2004) 13-22
16. Alpaugh M.L., Tomlinson J.S., Ye Y., and Barsky S.H. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 161 2 (2002) 619-628
17. Tomlinson J.S., Alpaugh M.L., and Barsky S.H. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 61 13 (2001) 5231-5241
18. Howard E.M., Lau S.K., Lyles R.H., et al. Expression of E-cadherin in high-risk breast cancer. J Cancer Res Clin Oncol 131 1 (2005) 14-18
19. Rahn J.J., Dabbagh L., Pasdar M., and Hugh J.C. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91 11 (2001) 1973-1982
20. Le M.G., Arriagada R., Bahi J., et al. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?. Breast 15 3 (2006) 355-362